The effects of adequate dietary calcium intake in patients with hypoparathyroidism non-adherent to treatment: a prospective randomized controlled trial.
Journal
Revista da Associacao Medica Brasileira (1992)
ISSN: 1806-9282
Titre abrégé: Rev Assoc Med Bras (1992)
Pays: Brazil
ID NLM: 9308586
Informations de publication
Date de publication:
2023
2023
Historique:
received:
28
07
2023
accepted:
03
08
2023
medline:
2
11
2023
pubmed:
1
11
2023
entrez:
1
11
2023
Statut:
epublish
Résumé
A significant problem that compels clinicians in the conventional treatment of hypoparathyroidism is patients' non-adherence to treatment. This study aimed to evaluate the effects of adequate Ca intake with dietary recommendations among hypoparathyroidism patients who persistently use Ca supplementation irregularly on plasma Ca and phosphate levels. This prospective, randomized, controlled study was conducted on patients diagnosed with chronic hypoparathyroidism who persistently interrupt Ca supplementation therapy and therefore have a hypocalcemic course. Patients with a total daily Ca intake below 800 mg were randomized. All patients were advised to keep the doses of active vitamin D and Ca supplements they were currently using. The patients in the study group (n=32) were advised to consume 1,000-1,200 mg of Ca daily, and the patients in the control group (n=35) were advised to continue their diet according to their daily habits. After 12 weeks of follow-up, the patients' laboratory values were compared between groups to assess treatment goals. The mean of the total Ca level was 8.56±0.36 mg/dL in the study group and was found to be significantly higher than that in the control group, which was 7.67±0.48 mg/dL (p<0.001). The mean serum phosphate and serum Ca-P product levels were significantly higher in the study group (p<0.001) but did not exceed the safe upper limits in any patient. A suitable increase in dietary Ca intake could effectively control hypocalcemia in patients with hypoparathyroidism who persistently interrupt the recommended calcium supplementation.
Identifiants
pubmed: 37909613
pii: S0104-42302023001100607
doi: 10.1590/1806-9282.20230406
pmc: PMC10610765
pii:
doi:
Substances chimiques
Calcium, Dietary
0
Calcium
SY7Q814VUP
Vitamin D
1406-16-2
Phosphates
0
Parathyroid Hormone
0
Types de publication
Randomized Controlled Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e20230406Références
Nutr Clin Pract. 2007 Jun;22(3):286-96
pubmed: 17507729
Eur J Endocrinol. 2019 Jun 1;181(3):P1-P19
pubmed: 31176307
J Clin Endocrinol Metab. 2020 Jun 1;105(6):
pubmed: 32322899
Lancet Diabetes Endocrinol. 2013 Dec;1(4):275-83
pubmed: 24622413
J Clin Endocrinol Metab. 2016 Jun;101(6):2313-24
pubmed: 26938200
J Bone Miner Res. 2022 Dec;37(12):2568-2585
pubmed: 36054621
J Clin Endocrinol Metab. 2016 Jun;101(6):2273-83
pubmed: 26943719
Front Horm Res. 2019;51:160-164
pubmed: 30641530
Eur J Endocrinol. 2019 Mar;180(3):P1-P22
pubmed: 30540559
J Clin Endocrinol Metab. 2013 Jan;98(1):137-44
pubmed: 23162103
J Am Diet Assoc. 2011 Apr;111(4):524-7
pubmed: 21443983
Clin Endocrinol (Oxf). 2012 Aug;77(2):200-6
pubmed: 22288727
Am J Clin Nutr. 1985 Feb;41(2):254-63
pubmed: 3838218
Endocrinol Metab Clin North Am. 2018 Dec;47(4):855-864
pubmed: 30390818
Perspect Infirm. 2011 Sep-Oct;8(5):5
pubmed: 21939083
Arch Osteoporos. 2022 Jan 24;17(1):22
pubmed: 35072832
Climacteric. 2010 Dec;13(6):578-84
pubmed: 19951084
Hormones (Athens). 2019 Mar;18(1):55-63
pubmed: 29876797
Br Med J. 1965 Jan 16;1(5428):161-4
pubmed: 14222594
Eur J Endocrinol. 2015 Aug;173(2):G1-20
pubmed: 26160136
J Bone Miner Res. 2022 Dec;37(12):2654-2662
pubmed: 36385517